"25807"^^ . . . . . . . . . . . . "Shrnut\u00ED v\u00FDsledk\u016F dal\u0161\u00EDch farmakokinetick\u00FDch hodnocen\u00ED l\u00E9kov\u00FDch interakc\u00ED\n\tSou\u010Dasn\u011B pod\u00E1van\u00E9 l\u00E9\u010Divo\n\tKoncentrace sou\u010Dasn\u011B\npod\u00E1van\u00E9ho l\u00E9\u010Diva\n\tKoncentrace topiram\u00E1tua\n\tAmitriptylin\nDihydroergotamin (peror\u00E1ln\u00ED a subkut\u00E1nn\u00ED)\nHaloperidol\nPropranolol\nSumatriptan (peror\u00E1ln\u00ED a subkut\u00E1nn\u00ED)\nPizotifen\nDiltiazem\nVenlafaxin\nFlunarizin\n\t(20% zv\u00FD\u0161en\u00ED cmax a AUC metabolitu nortryptylinu\n(\n(31% zv\u00FD\u0161en\u00ED AUC redukovan\u00E9ho metabolitu\n(17% zv\u00FD\u0161en\u00ED cmax u 4-OH propranololu (topiram\u00E1t 50\u00A0mg/12\u00A0hod)\n(\n(\n25% sn\u00ED\u017Een\u00ED AUC diltiazemu a 18% sn\u00ED\u017Een\u00ED DEA and ( DEM*\n(\n16% zv\u00FD\u0161en\u00ED AUC \n(topiram\u00E1t 50\u00A0mg/12\u00A0hod)b\n\tNS\n(\nNS\n9% a 16% zv\u00FD\u0161en\u00ED cmax, \n9% a\u00A017% zv\u00FD\u0161en\u00ED AUC (40, resp. 80\u00A0mg propranololu/12\u00A0hod)\nNS\n(\n20% zv\u00FD\u0161en\u00ED AUC\n(\n(\na Hodnoty v % jsou pr\u016Fm\u011Brn\u00E9 zm\u011Bny cmax nebo AUC u monoterapie\n( = \u017E\u00E1dn\u00FD \u00FA\u010Dinek na cmax a AUC ((\u00A015% zm\u011Bna) p\u016Fvodn\u00EDho l\u00E9\u010Diva\nNS = nebylo studov\u00E1no\n*DEA = des acetyl diltiazem, DEM = N-demethyl diltiazem\nb AUC flunarizinu se zvy\u0161uje o 14\u00A0% u subjekt\u016F u\u017E\u00EDvaj\u00EDc\u00EDch flunarizin samostatn\u011B."@cs . "24823"^^ . . . "1"^^ . . . . . . . . .